price month
strong result quarter cloud competit overhang
despit post posit result stock sold-off vs nbi
concern around potenti competitor expect updat
regeneron pozelimab healthi volunt data sc formul
roche/chugai data pnh patient earli
decemb abstract avail on-line nov et
could see volatil around updat clinic profil
set high bar agent first agent pnh
sc formul dose once-weekli market
also receiv inbound relat disclosur around
inquiri japanes ministri chanc catch
alexion subject compani clarifi investig
relat promot materi ahu japan indic soliri
narrow label japan local guidelin approv use
primari ahu compar broader use region
manag emphas patient still treat
suppli interrupt given narrow label ahu account
single-digit percentag
japan unlik
geographi may account impact would
minim even neg scenario
valuat outperform rate target price updat
model line actual result new manag guidanc take
non-gaap ep risk thesi includ
commerci regulatori clinic headwind
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
abl convert major soliri patient prior
launch biosimilar continu strength gmg launch
posit nmo data increas pipelin valu
unabl convert major soliri patient
prior launch biosimilar eu/row weak gmg
trend failur nmo decreas pipelin valu
 close
compani mention price
